Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in J Urol Retrieve available abstracts of 302 articles: HTML format

Single Articles

August 2024
1. NIU S, Ding X, Liu B, Ao L, et al
   Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by (18)F-Labeled Prostate-Specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-Center, Prosp
   J Urol. 2024;212:280-289.
   PubMed     Abstract available
   
   
   
2. VICKERS A, Vertosick E, Langsetmo L, Dahm P, et al
   Estimating the Effect of Radical Prostatectomy: Combining Data From the SPCG4 and PIVOT Randomized Trials With Contemporary Cohorts.
   J Urol. 2024;212:310-319.
   PubMed     Abstract available
   
   
   July 2024
3. GIESEN A, Devos G, Everaerts W, Joniau S, et al
   Letter: A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
   J Urol. 2024 Jul 8:101097JU0000000000004127. doi: 10.1097/JU.0000000000004127.
   PubMed    
   
   
   
4. RIVIERE P, Deshler LN, Morgan KM, Qiao EM, et al
   PSA Stratification for Predicting Advanced Prostate Cancer Events in Men Approaching Age-Limits for Recommended Screening.
   J Urol. 2024 Jul 5:101097JU0000000000004138. doi: 10.1097/JU.0000000000004138.
   PubMed     Abstract available
   
   
   
5. MOTA SM, Priester A, Shubert J, Bong J, et al
   Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent.
   J Urol. 2024;212:52-62.
   PubMed     Abstract available
   
   
   
6. MIAN BM, Bernstein A, Kaufman RP Jr, Fisher HAG, et al
   Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
   J Urol. 2024;212:227-228.
   PubMed    
   
   
   
7. NAHAS WC, Rodrigues GJ, Rodrigues Goncalves FA, Sawczyn GV, et al
   Perioperative, Oncological, and Functional Outcomes Between Robot-Assisted Laparoscopic Prostatectomy and Open Radical Retropubic Prostatectomy: A Randomized Clinical Trial.
   J Urol. 2024;212:32-40.
   PubMed     Abstract available
   
   
   
8. TILL C, Goodman PJ, Tangen C, Lucia MS, et al
   Letter: Survival After Selenium and Vitamin E Supplementation: Long-Term Followup of the Selenium and Vitamin E Cancer Prevention Trial.
   J Urol. 2024;212:228-229.
   PubMed    
   
   
   June 2024
9. NANDALUR KR, Shen C, Zhao L, Al-Katib S, et al
   Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
   J Urol. 2024 Jun 25:101097JU0000000000004117. doi: 10.1097/JU.0000000000004117.
   PubMed     Abstract available
   
   
   
10. LEWICKI P, Morgan T
    The Genomics and Natural History of MRI Visible vs. Invisible Prostate Cancer: Clinical Implications".
    J Urol. 2024 Jun 12:101097JU0000000000004104. doi: 10.1097/JU.0000000000004104.
    PubMed    
    
    
    
11. MOSES RA, Hunter AE, Brandes ER, Zhang Z, et al
    Patient-Reported Outcome Measures Following Hyperbaric Oxygen Therapy for Radiation Cystitis: Early Results From the Multicenter Registry for Hyperbaric Oxygen Therapy.
    J Urol. 2024;211:765-774.
    PubMed     Abstract available
    
    
    
12. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:802-803.
    PubMed    
    
    
    
13. SZABO RJ
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:801-802.
    PubMed    
    
    
    May 2024
14. BAHLER CD, Tachibana I, Tann M, Collins K, et al
    Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.
    J Urol. 2024 May 24:101097JU0000000000004032. doi: 10.1097/JU.0000000000004032.
    PubMed     Abstract available
    
    
    
15. HUSSAIN J, Sanchez-Salas R
    Letter: Point of View: What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2024 May 19:101097JU0000000000003924. doi: 10.1097/JU.0000000000003924.
    PubMed    
    
    
    
16. EMMETT L, Papa N, Hope TA, Fendler W, et al
    Beyond PI-RADS: Combining MRI PI-RADS and PSMA-PET/CT PRIMARY Score in a Composite (P) Score for More Accurate Diagnosis of Clinically Significant Prostate Cancer.
    J Urol. 2024 May 17:101097JU0000000000004010. doi: 10.1097/JU.0000000000004010.
    PubMed     Abstract available
    
    
    
17. TRINH QD, Labban M, Daniels D, Feldman A, et al
    Empowering Communities: Fostering Prostate Cancer Awareness and Resilience Among Men of Color.
    J Urol. 2024 May 4:101097JU0000000000003931. doi: 10.1097/JU.0000000000003931.
    PubMed    
    
    
    
18. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Clinically Significant Prostate Cancer Detection Following Transrectal and Transperineal Biopsy: Results of the Prostate Biopsy Efficacy and Complications Randomized Clinical Trial.
    J Urol. 2024 May 3:101097JU0000000000003979. doi: 10.1097/JU.0000000000003979.
    PubMed     Abstract available
    
    
    
19. QIAN H, Chi C, Tricard T, Zhu Y, et al
    A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy.
    J Urol. 2024;211:648-655.
    PubMed     Abstract available
    
    
    
20. MARIOTTI GC, Schmid BP, Gilberto GM, Garcia RG, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707.
    PubMed    
    
    
    
21. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:707-708.
    PubMed    
    
    
    April 2024
22. ST-LAURENT MP, Acland G, Hamilton SN, Hamm J, et al
    Long Term Second Malignancies in Prostate Cancer Patients Treated with Low-Dose-Rate Brachytherapy and Radical Prostatectomy.
    J Urol. 2024 Apr 11:101097JU0000000000003965. doi: 10.1097/JU.0000000000003965.
    PubMed     Abstract available
    
    
    
23. RUMPF F, Plym A, Vaselkiv JB, Penney KL, et al
    Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
    J Urol. 2024 Apr 10:101097JU0000000000003927. doi: 10.1097/JU.0000000000003927.
    PubMed     Abstract available
    
    
    
24. URABE F, Yoshioka T, Tashiro K, Kimura T, et al
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:622.
    PubMed    
    
    
    
25. MIAN BM
    Reply: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:623-624.
    PubMed    
    
    
    
26. CAKICI MC, Ozgur Kazan H, Yildirim A
    Letter: Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:624-625.
    PubMed    
    
    
    March 2024
27. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    PubMed     Abstract available
    
    
    
28. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    PubMed     Abstract available
    
    
    
29. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    PubMed     Abstract available
    
    
    
30. HOUGEN HY, Sjoberg DD, Thomas J, Mahal BA, et al
    Adding a Coefficient for Race to the 4Kscore Improves Calibration for Black Men.
    J Urol. 2024;211:392-399.
    PubMed     Abstract available
    
    
    February 2024
31. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part I: Introduction and Treatment Decision-Making at the Time of Suspected Biochemical Recurrence after Radical Prostatectomy.
    J Urol. 2024 Feb 19:101097JU0000000000003892. doi: 10.1097/JU.0000000000003892.
    PubMed     Abstract available
    
    
    
32. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part III: Salvage Therapy After Radiotherapy or Focal Therapy, Pelvic Nodal Recurrence and Oligometastasis, and Future Directions.
    J Urol. 2024 Feb 14:101097JU0000000000003890. doi: 10.1097/JU.0000000000003890.
    PubMed     Abstract available
    
    
    
33. MORGAN TM, Boorjian SA, Buyyounouski MK, Chapin BF, et al
    Salvage Therapy for Prostate Cancer: AUA/ASTRO/SUO Guideline Part II: Treatment Delivery for Non-metastatic Biochemical Recurrence After Primary Radical Prostatectomy.
    J Urol. 2024 Feb 14:101097JU0000000000003891. doi: 10.1097/JU.0000000000003891.
    PubMed     Abstract available
    
    
    
34. ESCOBAR AJ, Krishna S, Flowers KM, Abello A, et al
    Practical Use of Self-Adjusted Nitrous Oxide During Transrectal Prostate Biopsy: A Double-Blind Randomized Controlled Trial.
    J Urol. 2024;211:214-222.
    PubMed     Abstract available
    
    
    
35. MIAN BM, Feustel PJ, Aziz A, Kaufman RP Jr, et al
    Complications Following Transrectal and Transperineal Prostate Biopsy: Results of the ProBE-PC Randomized Clinical Trial.
    J Urol. 2024;211:205-213.
    PubMed     Abstract available
    
    
    
36. MISTRY NA, Sun Z, Sweis J, McCall C, et al
    Development and Validation of a Prostate Biopsy Risk Calculator in Black Men.
    J Urol. 2024;211:223-233.
    PubMed     Abstract available
    
    
    
37. BECHTEL MD, Michel C, Srinivasan P, Chalise P, et al
    Impact of Weight Management on Obesity-Driven Biomarkers of Prostate Cancer Progression.
    J Urol. 2024 Feb 1:101097JU0000000000003849. doi: 10.1097/JU.0000000000003849.
    PubMed     Abstract available
    
    
    
38. BERNARDINO R, Sayyid RK, Lajkosz K, Al-Daqqaq Z, et al
    Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through (18)F-DCFPyL?Prostate-Specific Membrane Antigen?Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients.
    J Urol. 2024 Feb 1:101097JU0000000000003850. doi: 10.1097/JU.0000000000003850.
    PubMed     Abstract available
    
    
    January 2024
39. TANEJA SS
    Urological Oncology: Prostate Cancer.
    J Urol. 2024 Jan 15:101097JU0000000000003835. doi: 10.1097/JU.0000000000003835.
    PubMed    
    
    
    
40. GARNICK MB, Hafron J, Crawford ED
    Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2024 Jan 5:101097JU0000000000003831. doi: 10.1097/JU.0000000000003831.
    PubMed    
    
    
    December 2023
41. VAN NESTE L, Henao R, Wojno KJ, Signes J, et al
    Development and Optimization of a Subtraction-Normalized Immunocyte Profiling Signature for Prostate Cancer Active Surveillance Risk Stratification.
    J Urol. 2023 Dec 26:101097JU0000000000003824. doi: 10.1097/JU.0000000000003824.
    PubMed     Abstract available
    
    
    
42. STIRA J, Gravina C, Lombardo R, De Nunzio C, et al
    Letter: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone?Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Dec 22:101097JU0000000000003830. doi: 10.1097/JU.0000000000003830.
    PubMed    
    
    
    
43. REZAEE ME, Pallauf M, Fletcher SA, Han M, et al
    Risk of Biochemical Recurrence in Patients with Grade Group 1 Prostate Cancer with Extraprostatic Extension Treated with Radical Prostatectomy.
    J Urol. 2023 Dec 18:101097JU0000000000003825. doi: 10.1097/JU.0000000000003825.
    PubMed     Abstract available
    
    
    November 2023
44. TOSOIAN JJ, Yu A, Brisbane WG
    Innovation and Progress for Screening and Management of Localized Prostate Cancer-What an Exciting Time.
    J Urol. 2023 Nov 27:101097JU0000000000003797. doi: 10.1097/JU.0000000000003797.
    PubMed    
    
    
    
45. JOYCE DD, Filson CP, Herrel LA
    What Are We Doing? The Incredible Expense and Uncertain Value of Localized Prostate Cancer Diagnostic and Therapeutic "Advances".
    J Urol. 2023 Nov 27:101097JU0000000000003798. doi: 10.1097/JU.0000000000003798.
    PubMed    
    
    
    
46. PAGADALA MS, Ryan S, Carter H, Javier-DesLoges J, et al
    Comparison of Genomic Inflation Estimates in Genome-Wide Association Studies Using Genetically-Identified Ancestry versus Self-Identified Race/Ethnicity in Prostate Cancer Patients in ELLIPSE Cohort.
    J Urol. 2023 Nov 27:101097JU0000000000003794. doi: 10.1097/JU.0000000000003794.
    PubMed    
    
    
    
47. LEPOR H
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Reply.
    J Urol. 2023 Nov 15:101097JU0000000000003782. doi: 10.1097/JU.0000000000003782.
    PubMed    
    
    
    
48. CHEN Y, Liang Z, Yan W
    Biopsy Assessment of Oncologic Control 3 Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men With Intermediate-Risk Prostate Cancer. Letter.
    J Urol. 2023 Nov 14:101097JU0000000000003781. doi: 10.1097/JU.0000000000003781.
    PubMed    
    
    
    
49. SESSINE MS, Radoiu CS, Qi J, Labardee C, et al
    Can MRI Help Inform Which Men with a History of Multifocal High Grade Prostatic Intraepithelial Neoplasia or Atypical Small Acinar Proliferation Remain at an Elevated Risk for Clinically Significant Prostate Cancer?
    J Urol. 2023 Nov 6:101097JU0000000000003775. doi: 10.1097/JU.0000000000003775.
    PubMed     Abstract available
    
    
    October 2023
50. CRAWFORD ED, Hafron JM, Debruyne F, Wallis C, et al
    Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.
    J Urol. 2023 Oct 5:101097JU0000000000003721. doi: 10.1097/JU.0000000000003721.
    PubMed     Abstract available
    
    
    
51. TERAMOTO Y, Wang Y, Miyamoto H
    Risk Stratification by Quantification of Perineural Cancer Invasion on Prostate Needle Core Biopsy: Should It Be Counted?
    J Urol. 2023;210:639-648.
    PubMed     Abstract available
    
    
    September 2023
52. MONTORSI F, Gandaglia G, Salonia A, Briganti A, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003683. doi: 10.1097/JU.0000000000003683.
    PubMed    
    
    
    
53. SHAH N, Ioffe V
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Sep 6:101097JU0000000000003682. doi: 10.1097/JU.0000000000003682.
    PubMed    
    
    
    August 2023
54. TANG W, Tang Y, Qi L, Zhang Y, et al
    BPH-related False Positive of PSMA-PET in the Diagnosis of Prostate Cancer: the Achilles' Heel of Biopsy-free Radical Prostatectomy?
    J Urol. 2023 Aug 30:101097JU0000000000003680. doi: 10.1097/JU.0000000000003680.
    PubMed     Abstract available
    
    
    
55. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Aug 25:101097JU0000000000003675. doi: 10.1097/JU.0000000000003675.
    PubMed    
    
    
    
56. JOYCE DD, Schulte PJ, Kwon ED, Dusetzina SB, et al
    Coping Mechanisms for Financial Toxicity Among Patients With Metastatic Prostate Cancer: A Survey-based Assessment.
    J Urol. 2023;210:290-298.
    PubMed     Abstract available
    
    
    
57. URKMEZ A, Davis JW
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Reply.
    J Urol. 2023;210:249.
    PubMed    
    
    
    
58. OZDEN E, Ozturk E, Turgut AT
    Freehand Versus Grid-based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications. Letter.
    J Urol. 2023;210:248-249.
    PubMed    
    
    
    
59. BERMAN DM, Lee AY, Lesurf R, Patel PG, et al
    Multimodal Biomarkers That Predict the Presence of Gleason Pattern 4: Potential Impact for Active Surveillance.
    J Urol. 2023;210:257-271.
    PubMed     Abstract available
    
    
    
60. CHANG K, Greenberg SA, Cowan JE, Parker R, et al
    Stability of Prognostic Estimation Using the CAPRA Score Incorporating Imaging-based vs Physical Exam-based Staging.
    J Urol. 2023;210:281-289.
    PubMed     Abstract available
    
    
    
61. BRITTON CJ, Sharma V, Fadel AE, Bearrick E, et al
    Vesicourethral Anastomotic Stenosis Following Radical Prostatectomy: Risk Factors, Natural History, and Treatment Outcomes.
    J Urol. 2023;210:312-322.
    PubMed     Abstract available
    
    
    July 2023
62. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jul 28:101097JU0000000000003633. doi: 10.1097/JU.0000000000003633.
    PubMed    
    
    
    
63. MONTORSI F, Stabile A, Gandaglia G, Briganti A, et al
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Jul 14:101097JU0000000000003614. doi: 10.1097/JU.0000000000003614.
    PubMed    
    
    
    
64. 
    MP44-04 Importance of the Ultrasound Characteristics of Regions of Interest by MRI and the Additional Target Biopsy Around Their Peri-hypoechoic Lesions in MR/TRUS Software Fusion Biopsy to Improve Detection Rate of Prostate Cancer.
    J Urol. 2023;210:223.
    PubMed    
    
    
    June 2023
65. YIM K, Ma C, Carlsson S, Lilja H, et al
    Free PSA and Clinically Significant and Fatal Prostate Cancer in the PLCO Screening Trial.
    J Urol. 2023 Jun 29:101097JU0000000000003603. doi: 10.1097/JU.0000000000003603.
    PubMed     Abstract available
    
    
    
66. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.
    J Urol. 2023 Jun 23:101097JU0000000000003598. doi: 10.1097/JU.0000000000003598.
    PubMed    
    
    
    
67. MAI Z, Zhou Z
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Letter.
    J Urol. 2023 Jun 22:101097JU0000000000003597. doi: 10.1097/JU.0000000000003597.
    PubMed    
    
    
    
68. JOYCE DD, Qin X, Sharma V, Boorjian SA, et al
    The Impact of Medicare Low-income Subsidy on Access to Treatment, Treatment Choice, and Oncologic Outcomes in Patients With Metastatic Prostate Cancer.
    J Urol. 2023 Jun 21:101097JU0000000000003592. doi: 10.1097/JU.0000000000003592.
    PubMed     Abstract available
    
    
    
69. YANAGISAWA T, Rajwa P, Kawada T, Mori K, et al
    Efficacy of Systemic Treatment in Prostate Cancer Patients with Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
    J Urol. 2023 Jun 20:101097JU0000000000003594. doi: 10.1097/JU.0000000000003594.
    PubMed     Abstract available
    
    
    
70. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Jun 19:101097JU0000000000003587. doi: 10.1097/JU.0000000000003587.
    PubMed    
    
    
    
71. WYSOCK JS, Rapoport E, Hernandez H, Gogaj R, et al
    Biopsy Assessment of Oncologic Control Three Years Following Primary Partial Gland Cryoablation: A Prospective Cohort Study of Men with Intermediate Risk Prostate Cancer.
    J Urol. 2023 Jun 7:101097JU0000000000003569. doi: 10.1097/JU.0000000000003569.
    PubMed     Abstract available
    
    
    
72. BRAILLON A
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening. Letter.
    J Urol. 2023 Jun 1:101097JU0000000000003567. doi: 10.1097/JU.0000000000003567.
    PubMed    
    
    
    May 2023
73. SHAH N, Ioffe V
    Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation. Letter.
    J Urol. 2023 May 30:101097JU0000000000003564. doi: 10.1097/JU.0000000000003564.
    PubMed    
    
    
    
74. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 18:101097JU0000000000003541. doi: 10.1097/JU.0000000000003541.
    PubMed    
    
    
    
75. ANDREWS JR, Sood A, Chapin BF
    Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer.
    J Urol. 2023 May 17:101097JU0000000000003495. doi: 10.1097/JU.0000000000003495.
    PubMed    
    
    
    
76. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 May 3:101097JU0000000000003477. doi: 10.1097/JU.0000000000003477.
    PubMed    
    
    
    
77. 
    LBA02-09 EMBARK: A Phase 3 Randomized Study of Enzalutamide or Placebo Plus Leuprolide Acetate and Enzalutamide Monotherapy in High-risk Biochemically Recurrent Prostate Cancer.
    J Urol. 2023 May 2:101097JU0000000000003518. doi: 10.1097/JU.0000000000003518.
    PubMed     Abstract available
    
    
    
78. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023;209:1026-1028.
    PubMed    
    
    
    
79. AVOLIO PP, Polascik TJ, Rastinehad A, de la Rosette J, et al
    Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. Letter.
    J Urol. 2023;209:848-849.
    PubMed    
    
    
    
80. SHAH RB
    Point/Counterpoint: Gleason Score 6/Grade Group 1 Prostate Cancer Should Renamed as "Non-cancer" to Improve Public Health-A Wrong Idea From a Pathologist's Perspective.
    J Urol. 2023 May 1:101097JU0000000000003510. doi: 10.1097/JU.0000000000003510.
    PubMed    
    
    
    
81. ZHOU M, Paner GP
    Grade Group 1 (Gleason Score 6) Prostate Cancer Should be Re-named to Improve Public Health: Pathologists' Perspective.
    J Urol. 2023 May 1:101097JU0000000000003511. doi: 10.1097/JU.0000000000003511.
    PubMed    
    
    
    April 2023
82. JANI AB, Ravizzini GC, Gartrell BA, Siegel BA, et al
    Diagnostic Performance and Safety of (18)F-rhPSMA-7.3 PET in Men with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT).
    J Urol. 2023 Apr 26:101097JU0000000000003493. doi: 10.1097/JU.0000000000003493.
    PubMed     Abstract available
    
    
    
83. LOWRANCE W, Dreicer R, Jarrard DF, Scarpato KR, et al
    Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023).
    J Urol. 2023 Apr 25:101097JU0000000000003452. doi: 10.1097/JU.0000000000003452.
    PubMed     Abstract available
    
    
    
84. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part I: Prostate Cancer Screening.
    J Urol. 2023 Apr 25:101097JU0000000000003491. doi: 10.1097/JU.0000000000003491.
    PubMed     Abstract available
    
    
    
85. WEI JT, Barocas D, Carlsson S, Coakley F, et al
    Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy.
    J Urol. 2023 Apr 25:101097JU0000000000003492. doi: 10.1097/JU.0000000000003492.
    PubMed     Abstract available
    
    
    
86. MARTINI A, Wever L, Soeterik TFW, Rakauskas A, et al
    Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma.
    J Urol. 2023 Apr 13:101097JU0000000000003442. doi: 10.1097/JU.0000000000003442.
    PubMed     Abstract available
    
    
    
87. BARABAN E, Erak E, Fatima A, Akbari A, et al
    Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer.
    J Urol. 2023 Apr 12:101097JU0000000000003461. doi: 10.1097/JU.0000000000003461.
    PubMed     Abstract available
    
    
    
88. HO MD, Ross AE, Eggener SE
    Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance.
    J Urol. 2023 Apr 12:101097JU0000000000003454. doi: 10.1097/JU.0000000000003454.
    PubMed     Abstract available
    
    
    
89. SHAH N, Ioffe V
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 11:101097JU0000000000003458. doi: 10.1097/JU.0000000000003458.
    PubMed    
    
    
    
90. KA-FUNG CHIU P, Leow JJ, Chiang CH, Mok A, et al
    Prostate Health Index Density Outperforms PSA Density in the Diagnosis of Clinically Significant Prostate Cancer in Equivocal MRI Prostates: A Multicenter Evaluation.
    J Urol. 2023 Apr 10:101097JU0000000000003450. doi: 10.1097/JU.0000000000003450.
    PubMed     Abstract available
    
    
    
91. GUIDOTTI A, Lombardo R, De Nunzio C
    Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. Letter.
    J Urol. 2023 Apr 10:101097JU0000000000003456. doi: 10.1097/JU.0000000000003456.
    PubMed    
    
    
    
92. HABASHY D, Reddy D, Peters M, Shah TT, et al
    Evaluation of Outcomes following Focal Ablative Therapy for Treatment of Localised Clinically Significant Prostate Cancer in Patients >70 Years: A Multi-institute, Multi-energy 15-year Experience.
    J Urol. 2023 Apr 4:101097JU0000000000003443. doi: 10.1097/JU.0000000000003443.
    PubMed     Abstract available
    
    
    
93. 
    Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
    J Urol. 2023;209:815.
    PubMed    
    
    
    March 2023
94. BREEN KE, Symecko H, Spielman K, Gebert R, et al
    Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients.
    J Urol. 2023 Mar 28:101097JU0000000000003186. doi: 10.1097/JU.0000000000003186.
    PubMed     Abstract available
    
    
    
95. TANEJA SS
    Urologic Oncology: Prostate Cancer.
    J Urol. 2023 Mar 23:101097JU0000000000003421. doi: 10.1097/JU.0000000000003421.
    PubMed    
    
    
    
96. JIN S, Wu L, Mai Z, Yan W, et al
    A Multicenter, Randomized, Single-Blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-Intermediate Risk Prostate Cancer. Letter.
    J Urol. 2023 Mar 16:101097JU0000000000003404. doi: 10.1097/JU.0000000000003404.
    PubMed    
    
    
    
97. ZHANG K, Teoh J, Laguna P, Ng CF, et al
    A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer. Reply.
    J Urol. 2023 Mar 16:101097JU0000000000003405. doi: 10.1097/JU.0000000000003405.
    PubMed    
    
    
    
98. SCHNEIDER AC, Chandrasekar T, Bowler N, Fogg R, et al
    Impact of an Expanded Definition of Family History on Outcomes of Active Surveillance for Prostate Cancer.
    J Urol. 2023 Mar 9:101097JU0000000000003396. doi: 10.1097/JU.0000000000003396.
    PubMed     Abstract available
    
    
    
99. HUSSAIN M, Sternberg CN, Efstathiou E, Fizazi K, et al
    Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial.
    J Urol. 2023;209:532-539.
    PubMed     Abstract available
    
    
    February 2023
100. SWAMI U, Hong A, El-Chaar NN, Ramaswamy K, et al
     The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer.
     J Urol. 2023 Feb 15:101097JU0000000000003370. doi: 10.1097/JU.0000000000003370.
     PubMed     Abstract available
     
     
     
101. LEAPMAN MS, Wang R, Loeb S, Seibert TM, et al
     Use of Monitoring Tests Among Patients With Localized Prostate Cancer Managed With Observation.
     J Urol. 2023 Feb 8:101097JU0000000000003159. doi: 10.1097/JU.0000000000003159.
     PubMed     Abstract available
     
     
     
102. PATEL N, Hughes A, Zhang H, Brisbane W, et al
     Utility of MRI for Localizing Prostate Cancer near the Urethra in Men Who are Candidates for Focal Gland Ablation.
     J Urol. 2023 Feb 8:101097JU0000000000003197. doi: 10.1097/JU.0000000000003197.
     PubMed     Abstract available
     
     
     
103. 
     Patient-reported Outcomes After External Beam Radiotherapy With Low Dose Rate Brachytherapy Boost vs Radical Prostatectomy for Localized Prostate Cancer: Five-year Results From a Prospective Comparative Effectiveness Study.
     J Urol. 2023;209:450.
     PubMed    
     
     
     
104. SCHWEIZER MT, True L, Gulati R, Zhao Y, et al
     Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.
     J Urol. 2023;209:354-363.
     PubMed     Abstract available
     
     
     January 2023
105. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2023 Jan 25:101097JU0000000000003180. doi: 10.1097/JU.0000000000003180.
     PubMed    
     
     
     
106. TOUIJER K, Plata Bello A
     Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Reply.
     J Urol. 2023 Jan 19:101097JU0000000000003178. doi: 10.1097/JU.0000000000003178.
     PubMed    
     
     
     
107. DE BARROS HA, Berrens AC, Donswijk ML, Wit EMK, et al
     Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node. Letter.
     J Urol. 2023 Jan 17:101097JU0000000000003177. doi: 10.1097/JU.0000000000003177.
     PubMed    
     
     
     
108. SAFARINEJAD MR, Safarinejad S, Shafiei N, Safarinejad S, et al
     Expression of Concern: G Protein beta3 Subunit Gene C825T Polymorphism and its Association with the Presence and Clinicopathological Characteristics of Prostate Cancer.
     J Urol. 2023 Jan 10:101097JU0000000000003145. doi: 10.1097/JU.0000000000003145.
     PubMed    
     
     
     
109. CARROLL P
     Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply.
     J Urol. 2023;209:73.
     PubMed    
     
     
     
110. SHOJI S, Kaya T, Tanaka Y, Uemura K, et al
     Usefulness of LacdiNAc-glycosylated Prostate-specific Antigen Density for Predicting Pathological Findings of Magnetic Resonance Imaging-transrectal Ultrasound Fusion Image-guided Prostate Biopsy for the Patients With Highest Prostate Imaging Reportin
     J Urol. 2023;209:187-197.
     PubMed     Abstract available
     
     
     December 2022
111. LIN DW
     Point-Counterpoint: Active Surveillance Should Still be Preferred Management for All (or Nearly All) Men with Low Risk Prostate Cancer.
     J Urol. 2022 Dec 27:101097JU0000000000003134. doi: 10.1097/JU.0000000000003134.
     PubMed    
     
     
     
112. TIMILSHINA N, Alibhai SMH, Tomlinson G, Sander B, et al
     Long-Term Outcomes following Active Surveillance of Low-Grade Prostate Cancer: A Population-Based Study Using a Landmark Approach.
     J Urol. 2022 Dec 7:101097JU0000000000003097. doi: 10.1097/JU.0000000000003097.
     PubMed     Abstract available
     
     
     
113. HIGANO CS, Hafron J
     Adherence With Oral Anticancer Therapies: Clinical Trial versus Real-World Experiences with a Focus on Prostate Cancer.
     J Urol. 2022 Dec 6:101097JU0000000000003081. doi: 10.1097/JU.0000000000003081.
     PubMed     Abstract available
     
     
     
114. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022;208:1349-1351.
     PubMed    
     
     
     
115. ANDREWS JR, Ahmed ME, Sharma V, Britton C, et al
     Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer.
     J Urol. 2022;208:1240-1249.
     PubMed     Abstract available
     
     
     
116. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Dec 1:101097JU0000000000003088. doi: 10.1097/JU.0000000000003088.
     PubMed    
     
     
     
117. ZHANG Y, Stopsack KH, Wu K, Song M, et al
     Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
     J Urol. 2022 Dec 1:101097JU0000000000003080. doi: 10.1097/JU.0000000000003080.
     PubMed     Abstract available
     
     
     November 2022
118. DE LA ROSETTE J, Dominguez-Escrig J, Zhang K, Teoh J, et al
     A Multicenter, Randomized, Single-blind, 2-Arm Intervention Study Evaluating the Adverse Events and Quality of Life After Irreversible Electroporation for the Ablation of Localized Low-intermediate Risk Prostate Cancer.
     J Urol. 2022 Nov 28:101097JU0000000000003051. doi: 10.1097/JU.0000000000003051.
     PubMed     Abstract available
     
     
     
119. PITTMAN A, Moses KA, Washington SL 3rd
     Urologists in Advocacy: The Key to Addressing Disparities in Prostate Cancer.
     J Urol. 2022 Nov 17:101097JU0000000000003000. doi: 10.1097/JU.0000000000003000.
     PubMed    
     
     
     
120. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Nov 16:101097JU0000000000003046. doi: 10.1097/JU.0000000000003046.
     PubMed    
     
     
     
121. DAHMANI C, Caron P, Simonyan D, Lacombe L, et al
     Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer.
     J Urol. 2022 Nov 14:101097JU0000000000003049. doi: 10.1097/JU.0000000000003049.
     PubMed     Abstract available
     
     
     
122. MARTINI A, Valerio M
     An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Reply.
     J Urol. 2022 Nov 11:101097JU0000000000003055. doi: 10.1097/JU.0000000000003055.
     PubMed    
     
     
     
123. BOWER PE
     An Algorithm to Personalize Nerve Sparing in Men With Unilateral High-risk Prostate Cancer. Letter.
     J Urol. 2022 Nov 11:101097JU0000000000003054. doi: 10.1097/JU.0000000000003054.
     PubMed    
     
     
     
124. LANNES F, Baboudjian M, Ruffion A, Rouy M, et al
     Radioisotope-Guided Lymphadenectomy for Pelvic Lymph Node Staging in Patients with Intermediate- and High-risk Prostate Cancer (The Prospective SENTINELLE Study).
     J Urol. 2022 Nov 4:101097JU0000000000003043. doi: 10.1097/JU.0000000000003043.
     PubMed     Abstract available
     
     
     
125. OZMAN O, Tillier CN, van Muilekom E, van de Poll-Franse LV, et al
     Financial Toxicity After Robot-Assisted Radical Prostatectomy and Its Relation with Oncologic, Functional Outcomes.
     J Urol. 2022;208:978-986.
     PubMed     Abstract available
     
     
     
126. DOAN P, Scheltema MJ, Amin A, Shnier R, et al
     Final Analysis of the Magnetic Resonance Imaging in Active Surveillance Trial.
     J Urol. 2022;208:1028-1036.
     PubMed     Abstract available
     
     
     
127. MAZZONE E, Gandaglia G, Stabile A, Bravi CA, et al
     Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy.
     J Urol. 2022;208:1046-1055.
     PubMed     Abstract available
     
     
     
128. FILSON CP, Zhu K, Huang Y, Zheng Y, et al
     Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
     J Urol. 2022;208:1037-1045.
     PubMed     Abstract available
     
     
     October 2022
129. PAUDEL R, Madan R, Qi J, Ferrante S, et al
     The Use and Short-term Outcomes of Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer Managed With Active Surveillance: The Initial Michigan Urological Surgery Improvement Collaborative Experience.
     J Urol. 2022 Oct 13:101097JU0000000000003012. doi: 10.1097/JU.0000000000003012.
     PubMed     Abstract available
     
     
     
130. HANSEN NF, Linscott JA, Hayn MH, Ryan ST, et al
     PSA testing behaviors for prostate cancer screening among U.S. immigrants: a cross-sectional analysis using the NHIS.
     J Urol. 2022 Oct 11:101097JU0000000000002993. doi: 10.1097/JU.0000000000002993.
     PubMed     Abstract available
     
     
     
131. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Oct 10:101097JU0000000000003008. doi: 10.1097/JU.0000000000003008.
     PubMed    
     
     
     
132. BABOUDJIAN M, Ploussard G
     Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort. Letter.
     J Urol. 2022 Oct 10:101097JU0000000000002991. doi: 10.1097/JU.0000000000002991.
     PubMed    
     
     
     
133. ZATTONI F, Marra G, Kasivisvanathan V, Grummet J, et al
     The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi
     J Urol. 2022;208:830-837.
     PubMed     Abstract available
     
     
     
134. RAVI P, Kwak L, Xie W, Kelleher K, et al
     Neoadjuvant Novel Hormonal Therapy Followed by Prostatectomy versus Up-Front Prostatectomy for High-Risk Prostate Cancer: A Comparative Analysis.
     J Urol. 2022;208:838-845.
     PubMed     Abstract available
     
     
     
135. OAKE JD, Shiff B, Harasemiw O, Tangri N, et al
     The Comparative Outcomes of Radical Prostatectomy versus Radiotherapy for Nonmetastatic Prostate Cancer: A Longitudinal, Population-Based Analysis.
     J Urol. 2022;208:846-854.
     PubMed     Abstract available
     
     
     September 2022
136. LABBATE CV, Klotz L, Morrow M, Cooperberg M, et al
     Focal Therapy for Prostate Cancer -Evolutionary Parallels to Breast Cancer Treatment.
     J Urol. 2022 Sep 21:101097JU0000000000002972. doi: 10.1097/JU.0000000000002972.
     PubMed     Abstract available
     
     
     
137. ROULEAU M, Neveu B, Caron P, Morin F, et al
     Extensive Alteration of Androgen Precursor Levels after Castration in Prostate Cancer Patients and Their Association with Active Androgen Level.
     J Urol. 2022 Sep 14:101097JU0000000000002923. doi: 10.1097/JU.0000000000002923.
     PubMed     Abstract available
     
     
     
138. JOYCE DD, Sharma V, Jiang DH, Van Houten HK, et al
     Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients.
     J Urol. 2022 Sep 12:101097JU0000000000002856. doi: 10.1097/JU.0000000000002856.
     PubMed     Abstract available
     
     
     
139. LOPEZ BM, Boville GA, Bernardos GB, Marckert XA, et al
     Focal Therapy of Prostate Cancer Index Lesion with Irreversible Electroporation. A Prospective Study with a Median Follow-Up of Three Years.
     J Urol. 2022 Sep 8:101097JU0000000000002970. doi: 10.1097/JU.0000000000002970.
     PubMed     Abstract available
     
     
     
140. DE LA CALLE CM, Mamawala MM, Landis P, Macura KJ, et al
     Clinical Significance of Perineural Invasion in Men with Grade Group 1 Prostate Cancer on Active Surveillance.
     J Urol. 2022 Sep 8:101097JU0000000000002963. doi: 10.1097/JU.0000000000002963.
     PubMed     Abstract available
     
     
     
141. SHEE K, Washington SL 3rd, Cowan JE, de la Calle CM, et al
     Gleason Grade 1 Prostate Cancer Volume at Biopsy is Associated with Upgrading, but Not Adverse Pathology or Recurrence after Radical Prostatectomy: Results from a Large Institutional Cohort.
     J Urol. 2022 Sep 6:101097JU0000000000002956. doi: 10.1097/JU.0000000000002956.
     PubMed     Abstract available
     
     
     
142. SHIRK JD, Reiter R, Wallen EM, Pak R, et al
     Effect of 3-Dimensional, Virtual Reality Models for Surgical Planning of Robotic Prostatectomy on Trifecta Outcomes: A Randomized Clinical Trial.
     J Urol. 2022;208:618-625.
     PubMed     Abstract available
     
     
     August 2022
143. DE B, Pasalic D, Barocas DA, Wallis CJD, et al
     Patient-Reported Outcomes after External Beam Radiotherapy with Low Dose-Rate Brachytherapy Boost versus Radical Prostatectomy for Localized Prostate Cancer: Five-Year Results from a Prospective Comparative Effectiveness Study.
     J Urol. 2022 Aug 25:101097JU0000000000002902. doi: 10.1097/JU.0000000000002902.
     PubMed     Abstract available
     
     
     
144. TROCK BJ, Jing Y, Mabey B, Sangale Z, et al
     Cell Cycle Progression Score, But Not PTEN Loss, Is an Independent Prognostic Factor for Metastasis in Intermediate- and High-Risk Prostate Cancer in Men Treated with and without Salvage Radiotherapy.
     J Urol. 2022 Aug 25:101097JU0000000000002922. doi: 10.1097/JU.0000000000002922.
     PubMed    
     
     
     
145. KIM IE JR, Pareek G
     The Key to Addressing Disparities in Prostate Cancer: Urologists in Advocacy?
     J Urol. 2022 Aug 24:101097JU0000000000002930. doi: 10.1097/JU.0000000000002930.
     PubMed    
     
     
     
146. RACHUBINSKI P, Witt JH, Budaus L, Zinke J, et al
     Precision-Guidance vs. Systematic Sampling: Optimizing Biopsy Assessment of Secondary Prostate Cancer Suspicious mpMRI Lesions.
     J Urol. 2022 Aug 24:101097JU0000000000002921. doi: 10.1097/JU.0000000000002921.
     PubMed     Abstract available
     
     
     
147. GABRIELSON AT, Choi U, Fletcher SA, Pavlovich CP, et al
     Lost in Transparency: The 21st Century Cures Act ("Open Notes") and Prostate Cancer Care.
     J Urol. 2022 Aug 19:101097JU0000000000002924. doi: 10.1097/JU.0000000000002924.
     PubMed    
     
     
     
148. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Aug 19:101097JU0000000000002909. doi: 10.1097/JU.0000000000002909.
     PubMed    
     
     
     
149. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Aug 16:101097JU0000000000002870. doi: 10.1097/JU.0000000000002870.
     PubMed    
     
     
     
150. ABUSAMRA SM, Solorzano MA, Luke M, Quarles J, et al
     Satisfaction with Clinician-Led Germline Genetic Counseling in Patients with Prostate Cancer.
     J Urol. 2022 Aug 5:101097JU0000000000002865. doi: 10.1097/JU.0000000000002865.
     PubMed     Abstract available
     
     
     
151. GLOGER S, Ubrig B, Boy A, Leyh-Bannurah SR, et al
     Bilateral Peritoneal Flaps Reduce Incidence and Complications of Lymphoceles after Robotic Radical Prostatectomy with Pelvic Lymph Node Dissection-Results of the Prospective Randomized Multicenter Trial ProLy.
     J Urol. 2022;208:333-340.
     PubMed     Abstract available
     
     
     
152. GOODE PS, Johnson TM 2nd, Newman DK, Vaughan CP, et al
     Perioperative Mobile Telehealth Program for Post-Prostatectomy Incontinence: A Randomized Clinical Trial.
     J Urol. 2022;208:379-387.
     PubMed     Abstract available
     
     
     
153. ABOU ZEINAB M, Beksac AT, Corse T, Talamini S, et al
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management.
     J Urol. 2022;208:369-378.
     PubMed     Abstract available
     
     
     July 2022
154. BRANT A, Lewicki P, Wu X, Sze C, et al
     Impact of Left-digit Age Bias in the Treatment of Localized Prostate Cancer.
     J Urol. 2022 Jul 28:101097JU0000000000002857. doi: 10.1097/JU.0000000000002857.
     PubMed     Abstract available
     
     
     
155. EASTHAM JA, Boorjian SA, Kirkby E
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline.
     J Urol. 2022 Jul 5:101097JU0000000000002854. doi: 10.1097/JU.0000000000002854.
     PubMed    
     
     
     
156. WESTHOFEN T, Buchner A, Kasivisvanathan V, Lennartz S, et al
     The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
     J Urol. 2022 Jul 5:101097JU0000000000002826. doi: 10.1097/JU.0000000000002826.
     PubMed     Abstract available
     
     
     
157. FAN S, Zhang Z, Wang J, Xiong S, et al
     Robot-Assisted Radical Prostatectomy Using the KangDuo Surgical Robot-01 System: A Prospective, Single-Center, Single-Arm Clinical Study.
     J Urol. 2022;208:119-127.
     PubMed     Abstract available
     
     
     
158. TOPS SCM, Grootenhuis JGA, Derksen AM, Giardina F, et al
     The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications.
     J Urol. 2022;208:109-118.
     PubMed     Abstract available
     
     
     June 2022
159. STINESEN KOLLBERG K, Holmberg E, Josefsson A, Hugosson J, et al
     Prostate-specific antigen (PSA) and biopsy contamination in the Goteborg-1 randomized, population-based, prostate cancer screening trial.
     J Urol. 2022 Jun 30:101097JU0000000000002835. doi: 10.1097/JU.0000000000002835.
     PubMed     Abstract available
     
     
     
160. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Jun 27:101097JU0000000000002796. doi: 10.1097/JU.0000000000002796.
     PubMed    
     
     
     
161. XUE X, Yang X, Ji Z, Xie Y, et al
     Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men. Letter.
     J Urol. 2022 Jun 21:101097JU0000000000002830. doi: 10.1097/JU.0000000000002830.
     PubMed    
     
     
     
162. ABOU ZEINAB M, Kaouk J
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Reply.
     J Urol. 2022 Jun 3:101097JU0000000000002785. doi: 10.1097/JU.0000000000002785.
     PubMed    
     
     
     
163. TIAN Y, Zhang H, Luo G
     The Multi-Institutional Experience in Single-Port Robotic Transvesical Simple Prostatectomy for Benign Prostatic Hyperplasia Management. Letter.
     J Urol. 2022 Jun 3:101097JU0000000000002784. doi: 10.1097/JU.0000000000002784.
     PubMed    
     
     
     
164. TURCHAN WT, Cutright D, Wu T, Leng JX, et al
     Hematuria following Post-Prostatectomy Radiotherapy: Incidence Increases with Long-Term Followup.
     J Urol. 2022;207:1236-1245.
     PubMed     Abstract available
     
     
     May 2022
165. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 May 20:101097JU0000000000002745. doi: 10.1097/JU.0000000000002745.
     PubMed    
     
     
     
166. STEPHENSON AJ, Vourganti S
     Pro: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
     J Urol. 2022 May 12:101097JU0000000000002776. doi: 10.1097/JU.0000000000002776.
     PubMed    
     
     
     
167. SIDDIQUI MM
     Con: MRI-Targeting Leads to Overtreatment of Prostate Cancer.
     J Urol. 2022 May 12:101097JU0000000000002777. doi: 10.1097/JU.0000000000002777.
     PubMed    
     
     
     
168. COLE AP, Chen X, Langbein BJ, Giganti F, et al
     Geographic Variability, Time Trends and Association of Preoperative MRI with Surgical Outcomes for Elderly US Men with Prostate Cancer: A SEER-Medicare Analysis.
     J Urol. 2022 May 10:101097JU0000000000002736. doi: 10.1097/JU.0000000000002736.
     PubMed     Abstract available
     
     
     
169. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery and Follow-up.
     J Urol. 2022 May 10:101097JU0000000000002758. doi: 10.1097/JU.0000000000002758.
     PubMed     Abstract available
     
     
     
170. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management.
     J Urol. 2022 May 10:101097JU0000000000002757. doi: 10.1097/JU.0000000000002757.
     PubMed     Abstract available
     
     
     
171. EASTHAM JA, Auffenberg GB, Barocas DA, Chou R, et al
     Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.
     J Urol. 2022 May 10:101097JU0000000000002759. doi: 10.1097/JU.0000000000002759.
     PubMed     Abstract available
     
     
     
172. ZHANG Y, Song M, Mucci LA, Giovannucci EL, et al
     Regular, Long-Duration Multivitamin Use and Risk of Overall and Aggressive Prostate Cancer in the Health Professionals Follow-Up Study.
     J Urol. 2022 May 6:101097JU0000000000002735. doi: 10.1097/JU.0000000000002735.
     PubMed     Abstract available
     
     
     
173. RADHAKRISHNAN A, Wallner LP, Skolarus TA, George AK, et al
     Exploring Variation in the Receipt of Recommended Active Surveillance for Men with Favorable-Risk Prostate Cancer.
     J Urol. 2022 May 6:101097JU0000000000002734. doi: 10.1097/JU.0000000000002734.
     PubMed     Abstract available
     
     
     
174. 
     Findings in 1,123 Men with Preoperative (68)Ga-Prostate-Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography and Multiparametric Magnetic Resonance Imaging Compared to Totally Embedded Radical Prostatectomy Histopathology: Im
     J Urol. 2022;207:1166.
     PubMed    
     
     
     
175. GONDOPUTRO W, Thompson J, Evans M, Bolton D, et al
     How Does Age Affect Urinary Continence following Robot-Assisted Radical Prostatectomy? A Prospective Multi-Institutional Study Using Independently Collected, Validated Questionnaires.
     J Urol. 2022;207:1048-1056.
     PubMed     Abstract available
     
     
     April 2022
176. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Apr 25:101097JU0000000000002705. doi: 10.1097/JU.0000000000002705.
     PubMed    
     
     
     
177. FRANLUND M, Mansson M, Godtman RA, Aus G, et al
     Results from 22 years of Follow-Up in the Goteborg Randomized Population-Based Prostate Cancer Screening Trial.
     J Urol. 2022 Apr 15:101097JU0000000000002696. doi: 10.1097/JU.0000000000002696.
     PubMed     Abstract available
     
     
     
178. LEWICKI P, Brant A, Shoag JE
     Re: A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
     J Urol. 2022 Apr 8:101097JU0000000000002700. doi: 10.1097/JU.0000000000002700.
     PubMed    
     
     
     
179. NYAME YA, Schraidt JA, Chakoian M, Nissenberg MG, et al
     A Patient-Centered Approach to Research Prioritization in Prostate Cancer.
     J Urol. 2022 Apr 8:101097JU0000000000002694. doi: 10.1097/JU.0000000000002694.
     PubMed     Abstract available
     
     
     
180. JIBARA GA, Perera M, Vertosick EA, Sjoberg DD, et al
     Association of Family History of Cancer with Clinical and Pathological Outcomes for Prostate Cancer Patients on Active Surveillance.
     J Urol. 2022 Apr 4:101097JU0000000000002668. doi: 10.1097/JU.0000000000002668.
     PubMed     Abstract available
     
     
     
181. DASKIVICH TJ, Gale R, Luu M, Naser-Tavakolian A, et al
     Variation in Communication of Competing Risks of Mortality in Prostate Cancer Treatment Consultations.
     J Urol. 2022 Apr 4:101097JU0000000000002675. doi: 10.1097/JU.0000000000002675.
     PubMed     Abstract available
     
     
     
182. PERERA M, Assel MJ, Benfante NE, Vickers AJ, et al
     Oncologic Outcomes of Total Length Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer.
     J Urol. 2022 Apr 1:101097JU0000000000002685. doi: 10.1097/JU.0000000000002685.
     PubMed     Abstract available
     
     
     March 2022
183. MONTORSI F, Mazzone E, Gandaglia G, Stabile A, et al
     Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
     J Urol. 2022 Mar 29:101097JU0000000000002680. doi: 10.1097/JU.0000000000002680.
     PubMed    
     
     
     
184. CHIERIGO F, Borghesi M, Mantica G, Terrone C, et al
     Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Reply.
     J Urol. 2022 Mar 29:101097JU0000000000002681. doi: 10.1097/JU.0000000000002681.
     PubMed    
     
     
     
185. DURSUN F, Wang CP, MacCarthy D, Mansour AM, et al
     Absolute PSA after 6 Months of Androgen Deprivation Therapy is a Predictor of Overall and Cancer Specific Mortality in Men with Hormone-Sensitive Prostate Cancer.
     J Urol. 2022 Mar 28:101097JU0000000000002676. doi: 10.1097/JU.0000000000002676.
     PubMed     Abstract available
     
     
     
186. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Mar 17:101097JU0000000000002511. doi: 10.1097/JU.0000000000002511.
     PubMed    
     
     
     
187. BRIGHT JR, Lis RT, Ku AT, Terrigino NT, et al
     PROSTATE-SPECIFIC Membrane Antigen Is a Biomarker for Residual Disease Following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer.
     J Urol. 2022 Mar 1:101097JU0000000000002492. doi: 10.1097/JU.0000000000002492.
     PubMed     Abstract available
     
     
     
188. KAN KM, Tin AL, Stearns GL, Eastham JA, et al
     De Novo Urinary Storage Symptoms Are Common after Radical Prostatectomy: Incidence, Natural History and Predictors.
     J Urol. 2022;207:601-608.
     PubMed     Abstract available
     
     
     
189. BAHOUTH Z, Laniado M, Fowler R, Charlesworth PJS, et al
     Positive Surgical Margins Rate of Retzius-Sparing Robot-Assisted Radical Prostatectomy in a Contemporary, Unselected Cohort.
     J Urol. 2022;207:609-616.
     PubMed     Abstract available
     
     
     February 2022
190. KAWA SM, Stroomberg HV, Larsen SB, Helgstrand JT, et al
     A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative TRUS-Biopsy with Long-Term Follow-Up.
     J Urol. 2022 Feb 25:101097JU0000000000002491. doi: 10.1097/JU.0000000000002491.
     PubMed     Abstract available
     
     
     
191. MAGNANI CJ, Hernandez-Boussard T, Baker LC, Goldhaber-Fiebert JD, et al
     Cost-Effectiveness Analysis and Microsimulation of Serial Multiparametric Magnetic Resonance Imaging in Active Surveillance of Localized Prostate Cancer.
     J Urol. 2022 Feb 25:101097JU0000000000002490. doi: 10.1097/JU.0000000000002490.
     PubMed     Abstract available
     
     
     
192. KANG DW, Fairey AS, Boule NG, Field CJ, et al
     A Randomized Trial of the Effects of Exercise on Anxiety, Fear of Cancer Progression and Quality of Life in Prostate Cancer Patients on Active Surveillance.
     J Urol. 2022 Feb 17:101097JU0000000000002334. doi: 10.1097/JU.0000000000002334.
     PubMed     Abstract available
     
     
     
193. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Feb 16:101097JU0000000000002477. doi: 10.1097/JU.0000000000002477.
     PubMed    
     
     
     
194. LOEB S, Borno HT, Gomez S, Ravenell J, et al
     Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.
     J Urol. 2022 Feb 4:101097JU0000000000002257. doi: 10.1097/JU.0000000000002257.
     PubMed     Abstract available
     
     
     
195. KACHANOV M, Leyh-Bannurah SR, Roberts MJ, Sauer M, et al
     Optimizing Combined Magnetic Resonance Imaging (MRI)-Targeted and Systematic Biopsy Strategies: Sparing the Multiparametric MRI-Negative Transitional Zone in Presence of Exclusively Peripheral Multiparametric MRI-Suspect Lesions.
     J Urol. 2022;207:333-340.
     PubMed     Abstract available
     
     
     
196. OTLES E, Denton BT, Qu B, Murali A, et al
     Development and Validation of Models to Predict Pathological Outcomes of Radical Prostatectomy in Regional and National Cohorts.
     J Urol. 2022;207:358-366.
     PubMed     Abstract available
     
     
     
197. CLEMENTS MB, Tin AL, Estes CL, Jibara G, et al
     Characterization of Symptoms after Radical Prostatectomy and Their Relation to Postoperative Complications.
     J Urol. 2022;207:367-374.
     PubMed     Abstract available
     
     
     January 2022
198. ANDRUSKA N, Fischer-Valuck BW, Waters M, Diaz EJ, et al
     Survival Outcomes in Men with Unfavorable Intermediate-Risk and High-Risk Prostate Cancer Treated with Prostate-only versus Whole Pelvic Radiation Therapy.
     J Urol. 2022 Jan 27:101097JU0000000000002455. doi: 10.1097/JU.0000000000002455.
     PubMed     Abstract available
     
     
     
199. KUPPERMANN D, Calais J, Marks LS
     Imaging Prostate Cancer: Clinical Utility of Prostate-specific Membrane Antigen (PSMA).
     J Urol. 2022 Jan 27:101097JU0000000000002457. doi: 10.1097/JU.0000000000002457.
     PubMed     Abstract available
     
     
     
200. SCHIFF H
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States. Letter.
     J Urol. 2022 Jan 26:101097JU0000000000002456. doi: 10.1097/JU.0000000000002456.
     PubMed    
     
     
     
201. ROSENBERG JE, Jarosek S, Spilseth B, Huang YH, et al
     Diagnosing Prostate Cancer: The Role of Intravesicular Prostatic Gland Protrusion on Accuracy of Prostate Biopsies.
     J Urol. 2022 Jan 26:101097JU0000000000002448. doi: 10.1097/JU.0000000000002448.
     PubMed     Abstract available
     
     
     
202. EGGENER S, Siemens DR
     Prostate Cancer, Decisional Regret and Exercise.
     J Urol. 2022 Jan 26:101097JU0000000000002453. doi: 10.1097/JU.0000000000002453.
     PubMed    
     
     
     
203. WANG M, Semerjian A, Lane BR, George AK, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort. Letter.
     J Urol. 2022 Jan 20:101097JU0000000000002442. doi: 10.1097/JU.0000000000002442.
     PubMed    
     
     
     
204. PLATA BELLO A, Apatov SE, Benfante NE, Rivero Belenchon I, et al
     Prevalence of High-Risk Prostate Cancer Metastasis to Cloquet's Ilioinguinal Lymph Node.
     J Urol. 2022 Jan 20:101097JU0000000000002439. doi: 10.1097/JU.0000000000002439.
     PubMed     Abstract available
     
     
     
205. SHAHAIT M, Cheaib JG, Davicioni E, Liu Y, et al
     Does Perioperative Testosterone Predict Post-prostatectomy Genomic Risk Score?
     J Urol. 2022 Jan 20:101097JU0000000000002440. doi: 10.1097/JU.0000000000002440.
     PubMed     Abstract available
     
     
     
206. PAN A, Reingold RE, Zhao JL, Moy A, et al
     Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.
     J Urol. 2022 Jan 12:101097JU0000000000002425. doi: 10.1097/JU.0000000000002425.
     PubMed     Abstract available
     
     
     
207. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2022 Jan 7:101097JU0000000000002413. doi: 10.1097/JU.0000000000002413.
     PubMed    
     
     
     
208. TANAKA T, Kawashima A, Rangel LJ, Schulte PJ, et al
     Long Term Risk of Clinical Progression Utilizing MRI Findings of Locally Recurrent Prostate Cancer in Patients with Biochemical Recurrence Following Radical Prostatectomy.
     J Urol. 2022 Jan 4:101097JU0000000000002421. doi: 10.1097/JU.0000000000002421.
     PubMed     Abstract available
     
     
     
209. NAYAK JG
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis. Reply.
     J Urol. 2022 Jan 4:101097JU0000000000002419. doi: 10.1097/JU.0000000000002419.
     PubMed    
     
     
     
210. GROSSO AA, Di Maida F, Mari A, Minervini A, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Health Care System: A Population-Based Analysis. Letter.
     J Urol. 2022 Jan 4:101097JU0000000000002418. doi: 10.1097/JU.0000000000002418.
     PubMed    
     
     
     
211. CHAPPIDI MR, Bell A, Cowan JE, Greenberg SA, et al
     The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer.
     J Urol. 2022 Jan 4:101097JU0000000000002420. doi: 10.1097/JU.0000000000002420.
     PubMed     Abstract available
     
     
     
212. LUCKENBAUGH AN, Wallis CJD, Huang LC, Wittmann D, et al
     Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes.
     J Urol. 2022 Jan 3:101097JU0000000000002370. doi: 10.1097/JU.0000000000002370.
     PubMed     Abstract available
     
     
     
213. PINTHUS JH, Duivenvoorden WCM, Klotz L, Mukherjee SD, et al
     Low Serum Testosterone in Men With Newly Diagnosed Androgen-Deprivation Therapy-Naive Prostate Cancer and Its Relationship to Cardiovascular Risk Factors-A Radical PC Substudy.
     J Urol. 2022 Jan 3:101097JU0000000000002384. doi: 10.1097/JU.0000000000002384.
     PubMed     Abstract available
     
     
     
214. LEE A, Chen K, Tay KJ
     Can We Avoid a Systematic Biopsy in Men with PI-RADS((R)) 5? Letter.
     J Urol. 2022;207:240-241.
     PubMed    
     
     
     
215. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Can We Avoid a Systematic Biopsy in Men with PI-RADS(R) 5? Reply.
     J Urol. 2022;207:241-242.
     PubMed    
     
     
     
216. CORKUM MT, Loblaw DA, Morton G, Louie AV, et al
     Radiation Oncologist Consultations Prior to Radical Prostatectomy: Disparities and Opportunities.
     J Urol. 2022;207:118-126.
     PubMed     Abstract available
     
     
     
217. CHANG P, Wagner AA, Regan MM, Smith JA, et al
     Prospective Multicenter Comparison of Open and Robotic Radical Prostatectomy: The PROST-QA/RP2 Consortium.
     J Urol. 2022;207:127-136.
     PubMed     Abstract available
     
     
     
218. WILLIAMS C, Ahdoot M, Daneshvar MA, Hague C, et al
     Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
     J Urol. 2022;207:95-107.
     PubMed     Abstract available
     
     
     
219. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
     Systematic versus Targeted Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy among Men with Visible Lesions.
     J Urol. 2022;207:108-117.
     PubMed     Abstract available
     
     
     December 2021
220. WASHINGTON SL 3RD, Gore JL, Nyame YA
     Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer.
     J Urol. 2021 Dec 30:101097JU0000000000002417. doi: 10.1097/JU.0000000000002417.
     PubMed    
     
     
     
221. ALKHATIB K, Labban M, Briggs L, Nguyen DD, et al
     Does Veteran Status Mitigate Racial Disparities in Prostate Cancer Screening? Analysis of Prostate-specific Antigen Screening Patterns in the 2018 Behavioral Risk Factor Surveillance System Data.
     J Urol. 2021 Dec 30:101097JU0000000000002379. doi: 10.1097/JU.0000000000002379.
     PubMed     Abstract available
     
     
     
222. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Dec 17:101097JU0000000000002377. doi: 10.1097/JU.0000000000002377.
     PubMed    
     
     
     
223. KAN WC, Hsieh KL, Chen YC, Ho CH, et al
     Comparison of Surgical or Medical Castration-Related Cardiotoxicity in Patients With Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002340. doi: 10.1097/JU.0000000000002340.
     PubMed     Abstract available
     
     
     
224. LONERGAN PE, Washington SL 3rd, Cowan JE, Zhao S, et al
     Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002335. doi: 10.1097/JU.0000000000002335.
     PubMed     Abstract available
     
     
     
225. KINNAIRD A, Yerram NK, O'Connor L, Brisbane W, et al
     MRI-guided Biopsy in Active Surveillance of Prostate Cancer.
     J Urol. 2021 Dec 2:101097JU0000000000002343. doi: 10.1097/JU.0000000000002343.
     PubMed     Abstract available
     
     
     
226. WAISMAN MALARET AJ, Chang P, Zhu K, Zheng Y, et al
     Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort.
     J Urol. 2021 Dec 2:101097JU0000000000002354. doi: 10.1097/JU.0000000000002354.
     PubMed     Abstract available
     
     
     
227. SHANKAR PR, Ellimoottil C, George AK, Hadj-Moussa M, et al
     Testing-Related Health Impact of Transrectal and Transperineal Prostate Biopsy as Assessed by Health Utilities.
     J Urol. 2021;206:1403-1410.
     PubMed     Abstract available
     
     
     November 2021
228. CHEN K, Murphy D, Lawrentschuk N
     Active Surveillance for Low-Risk Prostate Cancer: The Uphill Battles and the Unnecessary Ones.
     J Urol. 2021 Nov 17:101097JU0000000000002348. doi: 10.1097/JU.0000000000002348.
     PubMed    
     
     
     
229. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Nov 17:101097JU0000000000002326. doi: 10.1097/JU.0000000000002326.
     PubMed    
     
     
     
230. COOPERBERG MR, Lin DW, Morgan TM, Chapin BF, et al
     Active Surveillance: Very Much "Preferred" for Low-Risk Prostate Cancer.
     J Urol. 2021 Nov 15:101097JU0000000000002341. doi: 10.1097/JU.0000000000002341.
     PubMed    
     
     
     
231. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
     Timing of Radiotherapy after Radical Prostatectomy: Effects on Health-Related Quality of Life.
     J Urol. 2021;206:1192-1203.
     PubMed     Abstract available
     
     
     
232. KOWALCZYK KJ, Madi RH, Eden CG, Sooriakumaran P, et al
     Comparative Outcomes of Salvage Retzius-Sparing versus Standard Robotic Prostatectomy: An International, Multi-Surgeon Series.
     J Urol. 2021;206:1184-1191.
     PubMed     Abstract available
     
     
     October 2021
233. LEE MC, Erickson TR, Stock S, Howard LE, et al
     Association Between Delay to Radical Prostatectomy and Clinically Meaningful Outcomes Among Patients with Intermediate- and High-Risk Localized Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002304. doi: 10.1097/JU.0000000000002304.
     PubMed     Abstract available
     
     
     
234. LOZANO-LORCA M, Olmedo-Requena R, Rodriguez-Barranco M, Redondo-Sanchez D, et al
     Salivary Melatonin Rhythm and Prostate Cancer: CAPLIFE Study.
     J Urol. 2021 Oct 25:101097JU0000000000002294. doi: 10.1097/JU.0000000000002294.
     PubMed     Abstract available
     
     
     
235. DASKIVICH TJ, Luu M, Freedland SJ, Sandler H, et al
     Development and Validation of an Improved Pathological Nodal Staging System in Men With Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002256. doi: 10.1097/JU.0000000000002256.
     PubMed     Abstract available
     
     
     
236. YU W, Guo J
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. Letter.
     J Urol. 2021 Oct 25:101097JU0000000000002302. doi: 10.1097/JU.0000000000002302.
     PubMed    
     
     
     
237. RAVEENTHIRAN S, Yaxley WJ, Franklin T, Coughlin G, et al
     Findings in 1123 Men with Pre-operative (68)Ga-PSMA PET/CT and mpMRI Compared to Totally Embedded Radical Prostatectomy Histopathology. Implications for the Diagnosis and Management of Prostate Cancer.
     J Urol. 2021 Oct 25:101097JU0000000000002293. doi: 10.1097/JU.0000000000002293.
     PubMed     Abstract available
     
     
     
238. 
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Oct 18:101097JU0000000000002285. doi: 10.1097/JU.0000000000002285.
     PubMed    
     
     
     
239. KAPLAN-MARANS E
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS). Letter.J Urol; 206: 613.
     J Urol. 2021 Oct 11:101097JU0000000000002288. doi: 10.1097/JU.0000000000002288.
     PubMed    
     
     
     
240. ZHANG KW, Guha A
     Response to "Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS): Letter."
     J Urol. 2021 Oct 11:101097JU0000000000002289. doi: 10.1097/JU.0000000000002289.
     PubMed    
     
     
     
241. URKMEZ A, Demirel C, Altok M, Bathala TK, et al
     Freehand versus Grid-Based Transperineal Prostate Biopsy: A Comparison of Anatomical Region Yield and Complications.
     J Urol. 2021;206:894-902.
     PubMed     Abstract available
     
     
     
242. BHAT KRS, Covas Moschovas M, Sandri M, Dell'Oglio P, et al
     A Predictive Preoperative and Postoperative Nomogram for Postoperative Potency Recovery after Robot-Assisted Radical Prostatectomy.
     J Urol. 2021;206:942-951.
     PubMed     Abstract available
     
     
     September 2021
243. CHIERIGO F, Wenzel M, Wurnschimmel C, Flammia RS, et al
     Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
     J Urol. 2021 Sep 24:101097JU0000000000002250. doi: 10.1097/JU.0000000000002250.
     PubMed     Abstract available
     
     
     
244. LEAPMAN MS, Stone K, Wadia R, Park LS, et al
     Prostate Cancer Screening and Incidence Among Aging Persons Living with HIV.
     J Urol. 2021 Sep 24:101097JU0000000000002249. doi: 10.1097/JU.0000000000002249.
     PubMed     Abstract available
     
     
     
245. MARTINI A, Soeterik TFW, Haverdings H, Rahota RG, et al
     An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer.
     J Urol. 2021 Sep 22:101097JU0000000000002205. doi: 10.1097/JU.0000000000002205.
     PubMed     Abstract available
     
     
     
246. XUE AL, Kalapara AA, Ballok ZE, Levy SM, et al
     (68)Ga-PSMA PET SUVmax as a Predictor of Gleason Pattern 4 and Pathologic Upgrading in Intermediate Risk Prostate Cancer.
     J Urol. 2021 Sep 21:101097JU0000000000002254. doi: 10.1097/JU.0000000000002254.
     PubMed     Abstract available
     
     
     
247. KRAMER JJ, Gu L, Moreira D, Andriole G, et al
     Statin Use and Lower Urinary Tract Symptoms (LUTS) Incidence and Progression in Reduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial.
     J Urol. 2021 Sep 21:101097JU0000000000002199. doi: 10.1097/JU.0000000000002199.
     PubMed     Abstract available
     
     
     
248. MONTORSI F, Leni R, Briganti A, Gandaglia G, et al
     Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. Letter.
     J Urol. 2021 Sep 16:101097JU0000000000002245. doi: 10.1097/JU.0000000000002245.
     PubMed    
     
     
     
249. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Sep 9:101097JU0000000000002226. doi: 10.1097/JU.0000000000002226.
     PubMed    
     
     
     
250. GREENBERG SA, Washington SL 3rd, Lonergan PE, Cowan JE, et al
     Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen.
     J Urol. 2021;206:706-714.
     PubMed     Abstract available
     
     
     
251. EHDAIE B, Jibara G, Sjoberg DD, Laudone V, et al
     The Duration of Antibiotics Prophylaxis at the Time of Catheter Removal after Radical Prostatectomy: Clinically Integrated, Cluster, Randomized Trial.
     J Urol. 2021;206:662-668.
     PubMed     Abstract available
     
     
     
252. HINES L, Zhu D, DeMasi M, Babar M, et al
     A Comparison of Image-Guided Targeted Prostate Biopsy Outcomes by PI-RADS(R) Score and Ethnicity in a Diverse, Multiethnic Population.
     J Urol. 2021;206:586-594.
     PubMed     Abstract available
     
     
     
253. SOERENSEN SJC, Fan RE, Seetharaman A, Chen L, et al
     Deep Learning Improves Speed and Accuracy of Prostate Gland Segmentations on Magnetic Resonance Imaging for Targeted Biopsy.
     J Urol. 2021;206:604-612.
     PubMed     Abstract available
     
     
     August 2021
254. KIM M, Wu S, Lin SX, Crotty RK, et al
     Transperineal Multiparametric Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy Combined with Standard Template Improves Prostate Cancer Detection.
     J Urol. 2021 Aug 25:101097JU0000000000002168. doi: 10.1097/JU.0000000000002168.
     PubMed     Abstract available
     
     
     
255. TIMILSHINA N, Komisarenko M, Martin LJ, Cheung DC, et al
     Factors Associated With Discontinuation of Active Surveillance among Men With Low-Risk Prostate Cancer: A Population-Based Study.
     J Urol. 2021 Aug 20:101097JU0000000000001903. doi: 10.1097/JU.0000000000001903.
     PubMed     Abstract available
     
     
     
256. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Aug 18:101097JU0000000000002174. doi: 10.1097/JU.0000000000002174.
     PubMed    
     
     
     
257. COOLEY LF, Emeka AA, Meyers TJ, Cooper PR, et al
     Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
     J Urol. 2021 Aug 16:101097JU0000000000001937. doi: 10.1097/JU.0000000000001937.
     PubMed     Abstract available
     
     
     
258. KHEDIME S, Gelet A, Rouviere O, Lafon C, et al
     Salvage High-Intensity Focused Ultrasound for Local Recurrence in the Prostatic Bed after Prostatectomy and Adjuvant or Salvage Radiotherapy: Preliminary Results.
     J Urol. 2021;206:325-337.
     PubMed     Abstract available
     
     
     
259. TAFURI A, Iwata A, Shakir A, Iwata T, et al
     Systematic Biopsy of the Prostate can Be Omitted in Men with PI-RADS 5 and Prostate Specific Antigen Density Greater than 15.
     J Urol. 2021;206:289-297.
     PubMed     Abstract available
     
     
     
260. KUMAR RM, Fergusson DA, Lavallee LT, Cagiannos I, et al
     Performance Feedback May Not Improve Radical Prostatectomy Outcomes: The Surgical Report Card (SuRep) Study.
     J Urol. 2021;206:346-353.
     PubMed     Abstract available
     
     
     July 2021
261. RYAN CJ, Ke X, Lafeuille MH, Romdhani H, et al
     Management of Patients with Metastatic Castration-Sensitive Prostate Cancer in the Real-World Setting in the United States.
     J Urol. 2021 Jul 23:101097JU0000000000002121. doi: 10.1097/JU.0000000000002121.
     PubMed     Abstract available
     
     
     
262. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jul 20:101097JU0000000000002132. doi: 10.1097/JU.0000000000002132.
     PubMed    
     
     
     
263. FREEDLAND SJ, Howard LE, Ngo A, Ramirez-Torres A, et al
     Low Carbohydrate Diets and Estimated Cardiovascular and Metabolic Syndrome Risk in Prostate Cancer.
     J Urol. 2021 Jul 14:101097JU0000000000002112. doi: 10.1097/JU.0000000000002112.
     PubMed     Abstract available
     
     
     
264. ROMPRE-BRODEUR A, Marcq G, Tholomier C, Fugaru I, et al
     Role of Systematic Control Biopsies Following Partial Gland Ablation with High-Intensity Focused Ultrasound for Clinically Significant Prostate Cancer.
     J Urol. 2021 Jul 12:101097JU0000000000001934. doi: 10.1097/JU.0000000000001934.
     PubMed     Abstract available
     
     
     
265. PURYSKO AS, Bullen J, Valdez R, Auschof E, et al
     Influence of 5-Alpha Reductase Inhibitors on Prostate Cancer Detection With MRI: A Matched Cohort Study.
     J Urol. 2021 Jul 6:101097JU0000000000001932. doi: 10.1097/JU.0000000000001932.
     PubMed     Abstract available
     
     
     June 2021
266. TREMBLAY S, Summers-Trasiewicz L, Pouliot F, Crook JM, et al
     Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
     J Urol. 2021 Jun 29:101097JU0000000000001946. doi: 10.1097/JU.0000000000001946.
     PubMed     Abstract available
     
     
     
267. OAKE JD, Harasemiw O, Tangri N, Ferguson TW, et al
     The Association Between Income Status and Treatment Selection for Prostate Cancer in a Universal Healthcare System: A Population-Based Analysis.
     J Urol. 2021 Jun 28:101097JU0000000000001942. doi: 10.1097/JU.0000000000001942.
     PubMed     Abstract available
     
     
     
268. WILLIAMS C, Khondakar NR, Daneshvar MA, O'Connor LP, et al
     The Risk of Prostate Cancer Progression in Active Surveillance Patients With Bilateral Disease Detected by Combined MRI-Fusion and Systematic Biopsy.
     J Urol. 2021 Jun 28:101097JU0000000000001941. doi: 10.1097/JU.0000000000001941.
     PubMed     Abstract available
     
     
     
269. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Jun 21:101097JU0000000000001921. doi: 10.1097/JU.0000000000001921.
     PubMed    
     
     
     
270. INABA H, Kimura T, Onuma H, Kido M, et al
     Tumor Location and Pathological Features of Latent and Incidental Prostate Cancer in Contemporary Japanese Men. Reply.
     J Urol. 2021;205:1841-1842.
     PubMed    
     
     
     
271. VAN KALMTHOUT L, Braat A, de Keizer B, Lam M, et al
     Prospective Validation of Gallium-68 Prostate Specific Membrane Antigen-Positron Emission Tomography/Computerized Tomography for Primary Staging of Prostate Cancer. Reply.
     J Urol. 2021;205:1839-1840.
     PubMed    
     
     
     
272. AMIEL T, Wurnschimmel C, Heck M, Horn T, et al
     Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Obs
     J Urol. 2021;205:1663-1670.
     PubMed     Abstract available
     
     
     
273. DALY WC, Linscott JA, Han PKJ, Hayn MH, et al
     National Recommendations against Prostate Specific Antigen Screening versus Statewide Medicaid Expansion Initiatives: A Battle of the Titans.
     J Urol. 2021;205:1641-1647.
     PubMed     Abstract available
     
     
     
274. PATEL HD, Schwen ZR, Campbell JD, Gorin MA, et al
     Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial.
     J Urol. 2021;205:1681-1688.
     PubMed     Abstract available
     
     
     May 2021
275. AGARWAL N, McQuarrie K, Bjartell A, Chowdhury S, et al
     Apalutamide Plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study.
     J Urol. 2021 May 27:101097JU0000000000001841. doi: 10.1097/JU.0000000000001841.
     PubMed     Abstract available
     
     
     
276. LIFSHITZ K, Ber Y, Shenhar C, Nillson J, et al
     Cardiovascular Proteomics: A Post-hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist Vs GnRH Agonist Among Men with Advanced Prostate Cancer.
     J Urol. 2021 May 25:101097JU0000000000001879. doi: 10.1097/JU.0000000000001879.
     PubMed     Abstract available
     
     
     
277. CHEUNG DC, Alibhai SMH, Martin LJ, Komisarenko M, et al
     Real World Practice Patterns and Predictors of Continuous versus Intermittent ADT Use for Prostate Cancer in Older Men.
     J Urol. 2021 May 25:101097JU0000000000001876. doi: 10.1097/JU.0000000000001876.
     PubMed     Abstract available
     
     
     
278. MARSHALL CH, Chen Y, Kuo C, Cullen J, et al
     Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
     J Urol. 2021 May 18:101097JU0000000000001797. doi: 10.1097/JU.0000000000001797.
     PubMed     Abstract available
     
     
     
279. MACDONALD S, Matos A, Wambier C
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection With SARS-CoV-2. Letter.
     J Urol. 2021 May 17:101097JU0000000000001883. doi: 10.1097/JU.0000000000001883.
     PubMed    
     
     
     
280. KLEIN EA
     Androgen Deprivation Therapy in Men with Prostate Cancer Does Not Affect Risk of Infection with SARS-CoV-2. Reply.
     J Urol. 2021 May 17:101097JU0000000000001884. doi: 10.1097/JU.0000000000001884.
     PubMed    
     
     
     
281. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 May 17:101097JU0000000000001865. doi: 10.1097/JU.0000000000001865.
     PubMed    
     
     
     
282. SHAH N, Ioffe V
     Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role? Letter.
     J Urol. 2021 May 13:101097JU0000000000001880. doi: 10.1097/JU.0000000000001880.
     PubMed    
     
     
     
283. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Reply.
     J Urol. 2021;205:1528-1529.
     PubMed    
     
     
     
284. STAVRINIDES V, Giganti F, Allen C, Kirkham A, et al
     Followup of Men with PI-RADS(TM) 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.J Urol 2021; 205: 748.
     J Urol. 2021;205:1526-1528.
     PubMed    
     
     
     
285. PUNNEN S, Stoyanova R, Kwon D, Reis IM, et al
     Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.
     J Urol. 2021;205:1344-1351.
     PubMed     Abstract available
     
     
     
286. MATULEWICZ RS, Basak R, Zambrano I, Dearing BA, et al
     Patterns of Current Cigarette Smoking, Quit Attempts and Cessation Counseling among Survivors of Smoking-Related and Nonsmoking-Related Urological Malignancies: A Nationally Representative Cross-Sectional Analysis.
     J Urol. 2021;205:1444-1451.
     PubMed     Abstract available
     
     
     April 2021
287. RAMAN AG, Sarma KV, Raman SS, Priester AM, et al
     Optimizing Spatial Biopsy Sampling for the Detection of Prostate Cancer.
     J Urol. 2021 Apr 28:101097JU0000000000001832. doi: 10.1097/JU.0000000000001832.
     PubMed     Abstract available
     
     
     
288. CHIN JL, Lavi A, Metcalfe MJ, Siddiqui K, et al
     Long-Term Outcomes of Whole Gland Salvage Cryotherapy for Locally Recurrent Prostate Cancer Following Radiation Therapy: A Combined Analysis of Two Centers.
     J Urol. 2021 Apr 28:101097JU0000000000001831. doi: 10.1097/JU.0000000000001831.
     PubMed     Abstract available
     
     
     
289. LEYH-BANNURAH SR, Liakos N, Oelke M, Wagner C, et al
     Peri- and Postoperative Outcomes of Robot-Assisted Radical Prostatectomy in Prostate Cancer Patients with Prior Transurethral Subvesical Deobstruction: Results of a High-Volume Center.
     J Urol. 2021 Apr 27:101097JU0000000000001776. doi: 10.1097/JU.0000000000001776.
     PubMed     Abstract available
     
     
     
290. FAN L, Fei X, Zhu Y, Chi C, et al
     Distinct Response to Platinum-Based Chemotherapy Among Patients With Metastatic Castration-Resistant Prostate Cancer Harboring Alterations in Genes Involved in Homologous Recombination.
     J Urol. 2021 Apr 27:101097JU0000000000001819. doi: 10.1097/JU.0000000000001819.
     PubMed     Abstract available
     
     
     
291. RAJWA P, Mori K, Huebner NA, Martin DT, et al
     The Prognostic Association of Prostate MRI PI-RADS v2 Assessment Category and Risk of Biochemical Recurrence after Definitive Local Therapy for Prostate Cancer: A Systematic Review and Meta-analysis.
     J Urol. 2021 Apr 27:101097JU0000000000001821. doi: 10.1097/JU.0000000000001821.
     PubMed     Abstract available
     
     
     
292. STABILE A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, et al
     Association Between Lesion Location and Oncological Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy.
     J Urol. 2021 Apr 23:101097JU0000000000001787. doi: 10.1097/JU.0000000000001787.
     PubMed     Abstract available
     
     
     
293. TANEJA SS
     Urological Oncology: Prostate Cancer.
     J Urol. 2021 Apr 21:101097JU0000000000001814. doi: 10.1097/JU.0000000000001814.
     PubMed    
     
     
     
294. ZHANG KW, Reimers MA, Calaway AC, Fradley MG, et al
     Cardiovascular Events in Men with Prostate Cancer Receiving Hormone Therapy: An Analysis of the FDA Adverse Event Reporting System (FAERS).
     J Urol. 2021 Apr 19:101097JU0000000000001785. doi: 10.1097/JU.0000000000001785.
     PubMed     Abstract available
     
     
     
295. LIN PH, Howard L, Freedland SJ
     Impact of Low Carbohydrate Diet on Self-Report Fatigue and Weakness in Prostate Cancer Patients.
     J Urol. 2021 Apr 5:101097JU0000000000001780. doi: 10.1097/JU.0000000000001780.
     PubMed    
     
     
     
296. HALABI S, Jiang S, Terasawa E, Garcia-Horton V, et al
     Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.
     J Urol. 2021 Apr 5:101097JU0000000000001767. doi: 10.1097/JU.0000000000001767.
     PubMed     Abstract available
     
     
     
297. MATSUMOTO K, Omura M, Takeda T, Kosaka T, et al
     Grading of Multifocal Prostate Cancer Cases in which the Largest Volume and the Highest Grade do Not Coincide within One Lesion.
     J Urol. 2021 Apr 5:101097JU0000000000001765. doi: 10.1097/JU.0000000000001765.
     PubMed     Abstract available
     
     
     March 2021
298. BABAJIDE R, Carbunaru S, Nettey OS, Watson KS, et al
     Performance of Prostate Health Index in Biopsy Naive Black Men.
     J Urol. 2021;205:718-724.
     PubMed     Abstract available
     
     
     
299. UMARI P, Eden C, Cahill D, Rizzo M, et al
     Retzius-Sparing versus Standard Robot-Assisted Radical Prostatectomy: A Comparative Prospective Study of Nearly 500 Patients.
     J Urol. 2021;205:780-790.
     PubMed     Abstract available
     
     
     
300. TOSOIAN JJ, Trock BJ, Morgan TM, Salami SS, et al
     Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach.
     J Urol. 2021;205:732-739.
     PubMed     Abstract available
     
     
     
301. MENG X, Chao B, Chen F, Huang R, et al
     Followup of Men with PI-RADS 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy.
     J Urol. 2021;205:748-754.
     PubMed     Abstract available
     
     
     
302. FEUER Z, Meng X, Rosenkrantz AB, Kasivisvanathan V, et al
     Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort-How Many Clinically Significant Prostate Cancers are Missed?
     J Urol. 2021;205:740-747.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.